Merck fell 4% after second-quarter earnings of $2.02 per share slightly beat Bloomberg’s $2.02 estimate, but revenue of $15.81bn missed expectations of $15.89bn. The company maintained its quarterly dividend at $0.77 per share and announced plans to cut $3bn in costs by 2027.